nach oben

Current Treatment Options in Oncology

Erschienen in:

01.09.2014 | Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Optimal Treatment Strategies for Anal Cancer

verfasst von: Shahab Ahmed, MD, Cathy Eng, MD, FACP

Erschienen in: Current Treatment Options in Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Opinion statement

Squamous cell carcinoma (SCCA) of the anal canal is an underrecognized malignancy that is growing in annual incidence. Over the years, combined chemoradiation has been the mainstay of treatment for locally advanced SCCA of the anal canal. Currently, the human papilloma virus (HPV) vaccine is recommended to prevent the development of HPV and its associated precancerous lesion(s). Patients diagnosed with the human immunodeficiency virus (HIV+) are prone to develop anal cancer due to their high risk of contracting HPV infection. We will focus on the development and management of SCCA of the anal canal (both localized and metastatic), including special details on HIV-positive patients. Highlights will include the role of targeted therapy based on available literature. Our objective is to aid practicing physicians in formulating a treatment plan for both locally advanced and metastatic patients.

Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342(11):792–800.PubMedCrossRef

ACS, A.C.S. Cancer Facts & Figures 2014. 2014.

Thomas MK et al. Dominant role of HPV16 E7 in anal carcinogenesis. Virology. 2011;421(2):114–8.PubMedCentralPubMedCrossRef

Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000;12(4):345–52.PubMedCrossRef

Brewster DH, Bhatti LA. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer. 2006;95(1):87–90.PubMedCentralPubMedCrossRef

Edge ST, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Anus. In: AJCC Cancer Staging Manual. 7th edition. Springer. 2010;165–73.

Daling JR et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–80.PubMedCrossRef

Frisch M et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350–8.PubMedCrossRef

Jimenez W et al. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol. 2009;114(3):395–8.PubMedCrossRef

10.

Sunesen KG et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010;127(3):675–84.PubMedCrossRef

11.

Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12(5):524–34.PubMedCrossRef

12.

National Cancer Institute, N., Anal Cancer Treatment. 2014.

13.•

Chin YJ, Hong ST, Wo JY. Anal cancer: current and future treatment strategies. Gastrointest Cancer: Targets and Ther. 2013;3:19–27. This article is informative of current anal cancer treatment options.

14.

Frost DB et al. Epidermoid cancer of the anorectum. Cancer. 1984;53(6):1285–93.PubMedCrossRef

15.

Klotz Jr RG, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer. 1967;20(10):1727–45.PubMedCrossRef

16.

NCI. SEER Stat Fact Sheets: Anal Cancer. 2013; Available from: (http://seer.cancer.gov/statfacts/html/anus.html).

17.

Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report, 1974. Dis Colon Rectum. 1993;36(7):709–11.PubMedCrossRef

18.

Sato H, Koh PK, Bartolo DC. Management of anal canal cancer. Dis Colon Rectum. 2005;48(6):1301–15.PubMedCrossRef

19.

Cummings BJ et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25.PubMedCrossRef

20.

Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum. 1992;35(5):422–9.PubMedCrossRef

21.

Flam MS et al. Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases. Cancer. 1983;51(8):1378–87.PubMedCrossRef

22.

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348(9034):1049–54. doi:10.1016/S0140-6736(96)03409-5.

23.

Bartelink H et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040–9.PubMed

24.

Northover J et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123–8.PubMedCentralPubMedCrossRef

25.

Peiffert D et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941–8.PubMedCrossRef

26.

Ajani JA et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21.PubMedCrossRef

27.••

Gunderson LL et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51. This contains the recent updates on RTOG 98-11 trial.PubMedCentralPubMedCrossRef

28.•

Glynne Jones R, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. 2012 ASCO Annual Meeting Abstract.J Clin Oncol. 2012, 30 (suppl 15; abstr 4004). Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4004. This study assesses the complete response rate at different time points following combined modality therapy.

29.••

James RD et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516–24. This is a pivotal study in the management of squamous cell carcinoma of the anal canal.PubMedCrossRef

30.•

Eng C et al. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013;119(21):3769–75. This review supports the use of cisplatin in combination therapy for locally advanced squamous cell carcinoman of the anal canal.PubMedCrossRef

31.

Kam MK et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.PubMedCrossRef

32.

Ashman JB et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(3):765–71.PubMedCrossRef

33.

Kachnic LA et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.PubMedCentralPubMedCrossRef

34.

Milano MT et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.PubMedCrossRef

35.

Salama JK et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25(29):4581–6.PubMedCrossRef

36.

Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Cancer Netw. 2010;8(1):123–9.

37.

Bazan JG et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117(15):3342–51.PubMedCrossRef

38.

Kachnic LA et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):153–8.PubMedCrossRef

39.•

DeFoe SG et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma–clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol). 2012;24(6):424–31.CrossRef

40.•

Mitchell MP, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2013. This article describes the role of IMRT and its toxicity in the management of localized squamous cell carcinoma of the anal canal.

41.

Chuong MD et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6(2):39–45.PubMedCentralPubMed

42.

Ghouti L et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum. 2005;48(1):16–22.PubMedCrossRef

43.

Nilsson PJ et al. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep. 2006;16(3):443–9.PubMed

44.

Chessin DB et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12(2):104–10.PubMedCrossRef

45.

Butler CE, Gundeslioglu AO, Rodriguez-Bigas MA. Outcomes of immediate vertical rectus abdominis myocutaneous flap reconstruction for irradiated abdominoperineal resection defects. J Am Coll Surg. 2008;206(4):694–703.PubMedCrossRef

46.

Sunesen KG et al. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. 2009;16(1):68–77.PubMedCrossRef

47.

Lefevre JH et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg. 2009;250(5):707–11.PubMedCrossRef

48.

Nunez JE et al. Abdominoperineal resection in anal cancer: reconstruction of the perineum with a myocutaneous flap from the anterior rectus abdominis muscle. Cir Esp. 2011;89(1):31–6.PubMedCrossRef

49.••

Dewdney A, Rao S. Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncol. 2012;2012:756591. This informative reference describes the development on metastatic squamous cell cracinoma of the anal canal.PubMedCentralPubMed

50.

Wilking N et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol. 1985;15(3):300–2.PubMedCrossRef

51.

Hainsworth JD et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer. 2001;92(3):642–9.PubMedCrossRef

52.

Jhawer M et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Investig New Drugs. 2006;24(5):447–54.CrossRef

53.

Faivre C et al. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999;86(10):861–5.PubMed

54.

Ajani JA et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87(2):221–4.PubMedCrossRef

55.

Khater R et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep. 1986;70(11):1345–6.PubMed

56.

Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16(6):536–40.PubMedCrossRef

57.

Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008;9(4–6):400–7.PubMedCrossRef

58.•

Eng C, et al. Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal. 2012 Annual ASCO Meeting. J Clin Oncol 30, 2012 (suppl; abstr 4060). Available from: http://meetinglibrary.asco.org/content/100733-114. This refers to currently available options for treating metastatic squamous cell carcinoma of anal canal.

59.

Rogers JE, et al. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014.

60.

De Dosso S et al. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori. 2010;96(4):627–8.PubMed

61.

Lukan N et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77(5):293–9.PubMedCrossRef

62.•

NIH, N.I.o.H. International multicentre study in advanced anal cancer comparing cisplatin plus 5 FU vs carboplatin plus weekly paclitaxel (InterAACT). 2014 [cited 2014 02/11/2014].Available at: http://clinicaltrials.gov/ct2/show/NCT02051868?term=InterAACT&rank=1. This is the only phase II comparison trial to evaluate the different chemotherapy regimens for metastatic anal cancer.

63.

Van Damme N et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010;10:189.PubMedCentralPubMedCrossRef

64.

Paliga AA, et al. KRAS and EGFR gene mutation status in anal canal carcinoma. 2010 Gastrointestinal Cancers Symposium. General Poster Session C: Cancers of the Colon and Rectum. Abstr 352. Available from: http://meetinglibrary.asco.org/content/2056-72.

65.••

Garg M, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. 2012 ASCO Annual Meeting Abstracts. J Clin Oncol. 2012, 30 (suppl 15; abstr 4030). Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4030. This article is based on anti-EGFR roles on HIV negative and HIV patients with squamous cell carcinoma of the anal canal.

66.

Deutsch E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. 2011 ASCO Annual Meeting. General Poster Session, Gastrointestinal (Noncolorectal) Cancer. J Clin Oncol. 2011, 29 (suppl; abstr 4098). Available from: http://meetinglibrary.asco.org/content/81933-102.

67.

Patel P et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728–36.PubMedCrossRef

68.

Kim JH et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44(10):1496–502.PubMedCrossRef

69.

Oehler-Janne C et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26(15):2550–7.PubMedCrossRef

70.•

Rubinstein P, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for invasive anal carcinoma in HIV-positive patients receiving highly active anti-retroviral therapy versus non-HIV patients. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e14590). Available from: http://meetinglibrary.asco.org/content/101205-114. This study compares the outcomes of HIV negative patients with anal cancer who receive chemoradiation versus HIV positive patients with anal cancer who receive chemoradiation and HAART.

71.

Peddada AV et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1997;37(5):1101–5.PubMedCrossRef

72.

Hoffman R et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44(1):127–31.PubMedCrossRef

73.

Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006;66(1):206–11.PubMedCrossRef

74.

Stadler RF et al. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004;47(8):1305–9.PubMedCrossRef

75.•

National Comprehensive Cancer Network, N. Anal Carcinoma, NCCN guidelines. 2014 (Version 2.2013). This refers to the current guidelines for the management of anal cancer in the United States.

Titel: Optimal Treatment Strategies for Anal Cancer
verfasst von: Shahab Ahmed, MD
Cathy Eng, MD, FACP
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Current Treatment Options in Oncology / Ausgabe 3/2014
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-014-0298-0

Springer Medizin

Optimal Treatment Strategies for Anal Cancer

Opinion statement

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies

Genetics, Biomarkers, Hereditary Cancer Syndrome Diagnosis, Heterogeneity and Treatment: A Review

Liver-Directed Treatments for Metastatic Colorectal Cancer

Short-Course versus Long-Course Chemoradiation in Rectal Cancer—Time to Change Strategies?

Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review

Pulmonary Metastasectomy: Role of Pulmonary Metastasectomy and Type of Surgery

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie